TCW Group Inc. Invests $457,000 in Haemonetics Corporation (HAE)
TCW Group Inc. bought a new stake in shares of Haemonetics Corporation (NYSE:HAE) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,184 shares of the medical instruments supplier’s stock, valued at approximately $457,000.
A number of other institutional investors have also recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in Haemonetics Corporation by 2.1% during the 3rd quarter. Rhumbline Advisers now owns 104,669 shares of the medical instruments supplier’s stock valued at $4,696,000 after acquiring an additional 2,145 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of Haemonetics Corporation by 43.9% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 77,569 shares of the medical instruments supplier’s stock valued at $3,481,000 after buying an additional 23,680 shares during the period. Municipal Employees Retirement System of Michigan boosted its stake in shares of Haemonetics Corporation by 59.7% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 19,800 shares of the medical instruments supplier’s stock valued at $888,000 after buying an additional 7,400 shares during the period. BNP Paribas Arbitrage SA boosted its stake in shares of Haemonetics Corporation by 53.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 27,603 shares of the medical instruments supplier’s stock valued at $1,239,000 after buying an additional 9,607 shares during the period. Finally, Prudential Financial Inc. boosted its stake in shares of Haemonetics Corporation by 1.8% in the 3rd quarter. Prudential Financial Inc. now owns 90,892 shares of the medical instruments supplier’s stock valued at $4,078,000 after buying an additional 1,600 shares during the period.
Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research note on Friday. Morgan Stanley lifted their price objective on Haemonetics Corporation from $43.00 to $51.00 and gave the company an “equal weight” rating in a research note on Thursday, November 9th. Craig Hallum reiterated a “hold” rating and issued a $50.00 price objective (up previously from $40.00) on shares of Haemonetics Corporation in a research note on Wednesday, November 8th. Finally, Barrington Research lifted their price objective on Haemonetics Corporation from $48.00 to $57.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $53.33.
Shares of Haemonetics Corporation (HAE) opened at $57.99 on Friday. The firm has a market capitalization of $3,062.92, a P/E ratio of 35.58, a P/E/G ratio of 4.34 and a beta of 0.91. Haemonetics Corporation has a 52 week low of $36.44 and a 52 week high of $58.02. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.51 and a current ratio of 2.17.
Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.07. The firm had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics Corporation had a return on equity of 11.16% and a net margin of 0.50%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.38 earnings per share. analysts forecast that Haemonetics Corporation will post 1.7 EPS for the current year.
In other Haemonetics Corporation news, Director Ronald G. Gelbman sold 5,440 shares of Haemonetics Corporation stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $56.69, for a total transaction of $308,393.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Dan Goldstein sold 4,691 shares of Haemonetics Corporation stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $54.93, for a total value of $257,676.63. Following the transaction, the chief accounting officer now directly owns 3,747 shares in the company, valued at approximately $205,822.71. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,250 shares of company stock valued at $2,196,240. 1.20% of the stock is owned by company insiders.
About Haemonetics Corporation
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.